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Abstract The essential trace element zinc (Zn) is widely
required in cellular functions, and abnormal Zn homeo-
stasis causes a variety of health problems that include
growth retardation, immunodeﬁciency, hypogonadism, and
neuronal and sensory dysfunctions. Zn homeostasis is
regulated through Zn transporters, permeable channels, and
metallothioneins. Recent studies highlight Zn’s dynamic
activity and its role as a signaling mediator. Zn acts as an
intracellular signaling molecule, capable of communicating
between cells, converting extracellular stimuli to intracel-
lular signals, and controlling intracellular events. We have
proposed that intracellular Zn signaling falls into two
classes, early and late Zn signaling. This review addresses
recent ﬁndings regarding Zn signaling and its role in
physiological processes and pathogenesis.
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Abbreviations
BMP Bone morphogenetic protein
Ca Calcium
cAMP 30,50-Cyclic adenosine monophosphate
cGMP 30-50-Cyclic guanosine monophosphate
CIA Collagen-induced arthritis
EAE Experimental autoimmune encephalomyelitis
Erk1/2 Extracellular signal-regulated kinase 1 and 2
EZS Early zinc signaling
FceRI Fc epsilon receptor I
FGFR Fibroblast growth factor receptor
GPCR G protein-coupled receptor
GPR39 G protein-coupled receptor 39
gp130 Glycoprotein 130
IL-6 Interleukin-6
KO Knockout
LPS Lipopolysaccharide
LZS Late zinc signaling
mRNA Messenger RNA
MT Metallothionein
MT1/2-KO MT1 and MT2 double knockout
NF-jB Nuclear factor kappa B
NO Nitric oxide
PKC Protein kinase C
ROS Reactive oxygen species
SNOC S-nitrosocysteine
STAT3 Signal transducers and activators of
transcription 3
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Introduction
The presence of zinc (Zn) was discovered in Aspergillus
niger, the common bread mold, in the nineteenth century
[1]. Zn was not recognized as indispensable for human life
for almost another 100 years until the important discovery
by Prasad et al. [2]. Although Zn salts and Zn-related
compounds are normally colorless, unlike those of metals
such as copper and iron, making a biological study of Zn
more difﬁcult, recent advances in life science research have
contributed to unfolding its basic requirement for mam-
malian life [3], including the fact that Zn is pivotal for
mammalian oocytogenesis, even before conception [4, 5].
The essential trace element Zn is a structural constituent
in numerous proteins, including growth factors, cytokines,
receptors, enzymes, and transcription factors belonging to
cellular signaling pathways, and is essential for their bio-
logical activity [6, 7]. Emphasizing Zn’s physiological
relevance to life, a human genome bioinformatics study
revealed that approximately 10% of all proteins may bind
with Zn [8]. The biological functions of these Zn-binding
proteins would be maintained through cellular Zn levels,
which are tightly controlled by Zn transporters and chan-
nels, and by Zn-sensing molecules such as metallothioneins
(MTs) and metal-responsive-element-binding transcription
factor-1 [9–14] (Fig. 1).
Although many studies have focused on Zn homeostasis
and its biological relevance, recent advances in cell biol-
ogy and chemistry have highlighted the existence and
activity of free or labile Zn in cellular responses, partic-
ularly its neurotransmitter activity in synaptic vesicles [15,
16]. Dynamic changes in Zn levels in the brain correlating
to physiological experiences and long-term memories have
been documented [17, 18], suggesting that free Zn is
closely involved in neurotransmitter functions. There is
increasing evidence that Zn not only acts as a neuro-
transmitter to mediate intercellular communication, but
also acts as an intracellular signaling molecule, much like
calcium (Ca) [19]. Our observation that nuclear retention
of the Zn-ﬁnger transcription factor Snail requires the Zn
transporter Zrt/Irt-like protein (ZIP) 6/Liv1, which in the
zebraﬁsh gastrula organizer depends on signal transducers
and activators of transcription 3 (STAT3) activation
(Fig. 2a) [20], led to a hypothesis that Zn acts as an
intracellular signaling molecule. In this case, intracellular
Zn levels might change in response to extracellular stimuli
through changes in Zn transporter expression, affecting the
Fig. 1 Subcellular localization
of zinc (Zn) transporters and
metallothioneins (MTs).
Localization and potential
functions of Zn transporters
from the Slc39/Zrt/Irt-like
protein (ZIP)( blue) and Slc30/
ZnT (red) families, MT, and
metal-responsive-element-
binding transcription factor 1
(MTF1) within the cell, based
on currently available
information [30, 148–154].
Arrows show the predicted
direction of Zn mobilization. ER
endoplasmic reticulum
1124 J Biol Inorg Chem (2011) 16:1123–1134
123activation status of several intracellular signaling mole-
cules, including Snail. There is growing evidence that Zn
mediated by Zn transporters contributes to the regulation
of intracellular signaling pathways (Fig. 2a–e), as we will
discuss shortly.
We have proposed classifying intracellular Zn signals
into transcription-independent early Zn signaling (EZS)
and transcription-dependent late Zn signaling (LZS) [19]
(Fig. 3). EZS occurs in the ‘‘Zn wave’’ phenomenon in
mast cells, in which Zn levels change rapidly (within
several minutes) upon extracellular stimulation [21]. In
LZS, the intracellular Zn levels are altered several hours
after extracellular stimulation, through changes in Zn
transporter expression. Since many cytosolic proteins may
have Zn-binding potential, both EZS and LZS are expected
to be closely involved in a wide range of physiological
responses, including development, immune functions,
cancer progression, and hard and connective tissue disor-
ders [19, 22–24].
Here, we review new ﬁndings on the role of Zn sig-
naling in physiological processes and disease status, and
discuss the impact of EZS and LZS on biological events.
Zn transporters and MTs in Zn homeostasis, health,
and disease
Zn has wide-ranging effects on cellular functions [25, 26],
and imbalances in its homeostasis cause various types of
abnormalities in humans and in animal models [2, 15, 27].
The intracellular and extracellular Zn concentration and
distribution is controlled by MTs [28], and by Zn trans-
porters of the Slc39/ZIP and Slc30/ZnT families; these
transporters increase and decrease, respectively, the cyto-
solic Zn level [29, 30] (Fig. 1).
Molecular and genetic advances have uncovered the
biological signiﬁcance of Zn transporters. Mice with a
targeted disruption of ZIP1, ZIP2, or ZIP3 are sensitive to
dietary Zn deﬁciency during pregnancy [31, 32]. Mutations
in the human ZIP4 gene cause the inherited disorder
acrodermatitis enteropathica [33, 34], in which the intes-
tine’s ability to absorb dietary Zn is impaired. ZIP13-
knockout (KO) mice suffer from disorganization in
hard and connective tissues, including bone, teeth, skin,
and eyes [23, 24]. ZIP13 is involved in bone morphoge-
netic protein (BMP)/transforming growth factor beta
Fig. 2 Roles of ZIP and ZnT Zn transporter family members in
intracellular signaling. a The signal transducers and activators of
transcription 3 (STAT3) downstream target ZIP6 is required for
nuclear translocation of the Zn-ﬁnger transcription factor Snail, which
regulates gastrular cell movement in zebraﬁsh. b ZIP13 is required for
the nuclear translocation of Smads in bone morphogenetic protein
(BMP)/transforming growth factor beta (TGF-b) signaling, and is
involved in tooth, bone, and connective tissue development. c ZIP14,
which facilitates G protein-coupled receptor (GPCR) signaling by
inhibiting hormone-stimulated phosphodiesterase (PDE) in the
pituitary gland, liver, and cartilage, is required for endocrine reactions
and systemic growth. d ZnT5 controls protein kinase C (PKC)
translocation to the plasma membrane, leading to nuclear factor kappa
B( NF-jB)-mediated cytokine production in mast cells under Fc
epsilon receptor I (FceRI) signaling. e Lipopolysaccharide (LPS)
stimulation alters the expression of ZIP and ZnT family Zn
transporters, resulting in downregulated intracellular Zn levels,
followed by dendritic cell maturation and immune responses. TLR
Toll-like receptor
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123(TGF-b)-mediated Smad localization to the nucleus [23]
(Fig. 2b). In humans, the loss of ZIP13 function causes the
spondylocheiro dysplastic form of Ehlers–Danlos syn-
drome [23, 35]. ZIP14-KO mice exhibit retarded growth
and impaired gluconeogenesis, and ZIP14 has been shown
to regulate G protein-coupled receptor (GPCR) signaling,
including that through the parathyroid hormone receptor 1,
growth hormone releasing hormone receptor, and glucagon
receptor, by inhibiting phosphodiesterase activity (Fig. 2c)
[36]. The lethal milk mutant mice, which have a ZnT4 loss-
of-function mutation, suffer from an inherited Zn deﬁ-
ciency in the milk [37]. A similar abnormality, in which a
ZnT2 loss-of-function mutation reduces the concentration
of Zn in the milk, has been found in a human case [38].
ZnT8 is an islet b-cell-speciﬁc Zn transporter that provides
Zn to form insulin complexes [39]; its single-nucleotide
polymorphism is associated with type 2 diabetes [40], and
its deletion is accompanied by impaired insulin secretion
[41]. ZnT5-KO mice suffer from growth retardation and
osteogenic problems [42], and exhibit impaired cytokine
production in mast cells [43] (Fig. 2d).
Molecular and genetic approaches using fruit ﬂies have
contributed to our understanding of Zn transporter roles.
The Drosophila gene fear of intimacy, which shares simi-
larities with mammalian ZIP6/Liv1 and ZIP10 [44], is
essential for proper gonad formation, E-cadherin expres-
sion, and glial cell migration [45–47]. Zebraﬁsh Liv1
controls the epithelial–mesenchymal transition under
STAT3 activation [20] (Fig. 2a), suggesting that ZIP6 and/
or ZIP10 may have critical roles in cell migration; this was
also supported by studies using mammalian cells [48]. The
Drosophila counterpart of ZIP7, Catsup, controls melanin
synthesis [49]. Investigation of the Drosophila breathless
mutant, which lacks functional ﬁbroblast growth factor
receptors (FGFRs), suggested that Catsup protein facili-
tates FGFR signaling by inhibiting FGFR protein down-
regulation [50]. A functional connection between ZIP7 and
signaling was proposed by a study using cancer cells; ZIP7
positively regulates tyrosine kinases through Zn inhibition
of protein tyrosine phosphatases [51]. These reports indi-
cate that ZIP7’s importance in various biological events
may be evolutionarily conserved.
MT molecules are also important in Zn homeostasis
[28]; they will be only brieﬂy mentioned here, since they
are well described in other articles in this volume. MT was
ﬁrst discovered as a cadmium-binding protein in horse
kidneys [52]. Their unique cysteine-rich structure, Zn-
binding ability, and expression regulation have drawn
many researchers to study MTs, and genetic advances
using mouse models have enlarged our understanding of
MT activity both in physiological and pathogenic processes
such as inﬂammation. MTs protect against ﬁbrinolytic
disturbance and organ damage induced by the bacterial
endotoxin lipopolysaccharide (LPS) and ozone (O3)[ 53].
MTs may protect against allergic inﬂammation through
their antioxidant potential, and by suppressing inﬂamma-
tory cytokines, including interleukin-1 beta [54]. MT
defects may cause severe inﬂammatory responses in mul-
tiple sclerosis, Helicobacter-induced gastritis, and LPS-
mediated lung injury [55–57], suggesting that MTs and Zn
may coordinate to protect against various inﬂammatory
conditions in mice [58]. Collectively, these reports strongly
Fig. 3 Early and late Zn
signaling. Intracellular Zn
signaling falls into two types:
early Zn signaling (left), in
which an extracellular stimulus
directly induces elevated Zn
levels within several minutes by
releasing Zn from a Zn store
such as ER or MTs, and late Zn
signaling (right), which is
induced several hours after
stimulation and is dependent on
a transcriptional change in Zn
transporter expression. Zn
waves in mast cells are an
example of early Zn signaling
(see Fig. 6)
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123suggest that MTs and Zn transporters are linked with a
wide variety of biological events, disorders, and regulatory
functions.
Zn in allergy and immunology
Zn deﬁciency in humans accompanies many chronic dis-
eases and is frequently a dietary problem. Zn homeostasis
experiments using mouse models appear to be ideal for
determining the impact of a single element nutritional
deﬁciency on immune function, at both the cellular level
and the molecular level [59]. Numerous results from ani-
mal models have conﬁrmed that Zn deﬁciency induces
thymic atrophy and lymphopenia, compromises cell- and
antibody-mediated responses, and results in increased
infection rates and durations [60–64].
Intracellular Zn levels and distribution have been
investigated using Zn probes, which enable the imaging of
distinct pools of Zn in allergy-related cells. For instance,
mast cell granules ﬂuoresce intensely with zinquin [65].
Airway epithelial cells are also rich in Zn [66]. In addition,
Zn is found in the intracellular and extracellular matrix and
accumulates in skin tissues following injury [67]. Fur-
thermore, Zn accelerates wound healing and the reepi-
thelialization process [68, 69]. It has been reported that Zn
deﬁciency increases allergic eosinophilic inﬂammation,
whereas dietary Zn supplementation attenuates its intensity
[70]. Zn deﬁciency is a risk factor for developing asthma
[71, 72]. These reports suggest that Zn is involved in the
development of allergic disease. In addition, high levels of
ZIP2 messenger RNA (mRNA) are found in the leukocytes
of asthmatic infants [73]. However, the precise roles of Zn
and Zn transporters in allergy-related cells are not well
understood.
We found that Zn is involved in regulating allergic
response in mast cells [74]. In these cells, Zn chelators
inhibit histamine release, cytokine production, and lipid
mediator secretion, and these inhibitory effects are rescued
by Zn supplementation. Other metal chelators do not affect
mast cell function. These results indicate that Zn is crucial
for mast cell degranulation and for cytokine production.
Similarly, depleting Zn with a Zn chelator, or with the
clinically used heavy-metal chelator 2-3-dimercaptopro-
pane-1-sulfonate, inhibits the mRNA expression of che-
mokines such as eotaxin in human lung cell lines [75].
Recently, Nishida et al. [43] reported that ZnT5 plays
crucial roles in mast cell activation and mast cell-mediated
allergic reactions (Fig. 2d). ZnT5 mRNA is highly
expressed in mast cells, and its level is enhanced by Fc
epsilon receptor I (FceRI) stimulation, suggesting that
ZnT5 is involved in FceRI-mediated allergic reactions.
ZnT5-KO mice have defects in mast cell delayed-type
allergic reactions such as contact hypersensitivity, but not
in immediate-type reactions such as anaphylaxis [43].
Consistent with this in vivo analysis, ZnT5 is required for
FceRI-mediated cytokine production but not for degranula-
tion in mast cells. In ZnT5-KO mast cells, FceRI-induced
interleukin-6(IL-6)andtumornecrosisfactoralpha(TNF-a)
mRNA are reduced. Furthermore, the FceRI-induced trans-
location of protein kinase C (PKC) to the plasma membrane
and the translocation of nuclear factor kappa B (NF-jB)
to the nucleus are impaired in ZnT5-KO mast cells.
Thus, ZnT5 is selectively needed for mast cell-mediated
delayed-type allergic responses, and is a novel player in
PKC/NF-jB signaling. This raises the question, presently
unanswered, of how ZnT5 regulates the plasma mem-
brane translocation of PKC. PKC contains Zn-binding
motifs in its phorbol 12-myristate 13-acetate binding
sites, and Zn is essential to its structure [76, 77].
Mutational analysis shows that PKC’s Zn-binding site is
essential for PKC’s translocation to the plasma mem-
brane (Fig. 4), suggesting a crucial link between ZnT5
and PKC activation.
In addition to its role in allergy-related cells, Zn is
involved in the control of both dendritic and T cells. The
Fig. 4 Zn and Zn transporters are indispensable for FceRI-mediated
mast cell activation. Zn is required for multiple steps of FceRI-
induced mast cell activation, including degranulation and cytokine
production. Cytosolic Zn regulates the FceRI-induced granule trans-
location process, which is mediated by a Fyn/Grb2-associated binder
2( Gab2)/Ras homologue gene family member A (RhoA)-mediated
calcium-independent pathway. Zn and ZnT5 are also required for the
translocation of PKC to the plasma membrane and the subsequent
nuclear translocation of NF-jB, which leads to the production of
cytokines such as interleukin-6 (IL-6) and tumor necrosis factor alpha
(TNF-a). IKKb I-kappa B kinase beta, IkBa I-kappa B alpha
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123intracellular free Zn concentration decreases in mouse
dendritic cells exposed to the endotoxin LPS, which is a
Toll-like receptor (TLR) stimulant. Furthermore, artiﬁ-
cially depleting intracellular Zn with a Zn chelator triggers
dendritic cell maturation. On the other hand, artiﬁcially
elevating the intracellular Zn level suppresses the dendritic
cells’ ability to respond to LPS. LPS stimulation affects Zn
transporter expression, effectively increasing (ZIP family)
or decreasing (ZnT family) the level of intracellular Zn.
Importantly, the ectopic expression of ZIP6, which is
reduced by LPS stimulation, suppresses dendritic cell
maturation and inhibits CD4
? T cell-stimulatory activity
[78]. A similar Zn effect is observed in live animals; LPS
injection reduces the intracellular free Zn and ZIP6 mRNA
levels in dendritic cells, and treatment with Zn-depleting
agents increases dendritic cell maturation [78]. These
results show that extracellular stimuli, by affecting Zn
transporter expression and thus changing the intracellular
Zn levels, play a role in the process of dendritic cell mat-
uration, an important step in T cell activation and immune
response (Fig. 2e).
Zn is also involved in T cell function. It has been
reported that Zn-supplying compounds such as polaprezinc
and Z-103 suppress autoimmune disease models [79, 80],
suggesting that Zn might suppress autoimmune disease by
inhibiting T cell activation. However, the details of the
mechanism behind this suppression are not understood.
One of the important questions involved is how Zn affects
T helper 17 (Th17) cells, since Th17 cell development is
controlled by IL-6-induced STAT3 activation [81–85], and
Th17 cells are important in autoimmune diseases such as
collagen-induced arthritis (CIA), mutated IL-6 receptor and
signal transducer glycoprotein 130 (gp130): Y759F gp130-
induced arthritis, and experimental autoimmune encepha-
lomyelitis (EAE) [86, 87]. CIA and EAE are mediated by
antigen-speciﬁc Th17 cells, whose development is con-
trolled under STAT3 activation. As expected, adding Zn to
drinking water signiﬁcantly suppresses both CIA and EAE
development in animal models [88]. Zn suppresses Th17
cell development, which is dependent on the IL-6/STAT3
signaling pathway, during the induction of autoimmune
diseases (Fig. 5). In fact, Zn directly inhibits STAT3’s
tyrosine phosphorylation by Janus kinase without affecting
the phosphorylation ability of Janus kinase proteins.
STAT3 protein itself is unfolded by Zn binding, indicating
that Zn directly binds STAT3 and inhibits its activation
[88].
It has also been reported that MTs are involved in
asthma and ultraviolet B-induced contact hypersensitivity.
Ovalbumin-induced airway inﬂammation is worse in the
MT1 and MT2 double-KO (MT1/2-KO) mice than in wild-
type mice. The cellular proﬁle of the bronchoalveolar ﬂuid,
lung histology ﬁndings, and expression of proinﬂammatory
molecules in the lungs were consistent with increased air-
way inﬂammation in MT1/2-KO mice [54]. In another
allergy model, moderate daily ultraviolet B doses caused
signiﬁcantly more immunosuppression in MT1/2-KO mice
than in wild-type mice [89]. These ﬁndings indicate that Zn
transporters and Zn-related molecules are indispensably
involved in allergic and immune responses and regulate a
variety of signaling processes (Figs. 4, 5).
Zn signaling
As recent advances have revealed the existence of free or
labile Zn in many physiological situations, Zn has been
increasingly recognized as a potential signaling molecule
[15, 16, 19].
Zn as a neurotransmitter, or the ﬁrst messenger in cell–
cell communication
An exchangeable Zn ion in the brain was ﬁrst documented
by Maske [90] in 1955. Zn is highly concentrated in syn-
aptic vesicles and is released with glutamate in an activity-
dependent manner [91]. Recently, Zn-imaging techniques
using ﬂuorescence sensor molecules, which allow the Zn
concentration and distribution to be analyzed in real time,
have been widely applied [92]. Microﬂuorescence imaging
of Zn secretion showed that Zn is released from hippo-
campal mossy ﬁber terminal vesicles into the surrounding
Fig. 5 Zn suppresses T helper 17 (Th17) cell development by
inhibiting STAT3 activation. Peripheral naive CD4
? T cell precursor
cells can differentiate into three subsets of effector T cells (Th1, Th2,
and Th17). The differentiation of these subsets is governed by
selective cytokines, and each subset accomplishes specialized func-
tions. Th17 cells, which are critical for the development of
inﬂammation and autoimmune disease, are induced by IL-6 and
tumor necrosis factor beta (TGF-b). Zn directly binds STAT3,
inhibiting its activation by IL-6 and suppressing autoimmune diseases
such as experimental autoimmune encephalomyelitis (EAE) and
collagen-induced arthritis (CIA). P tyrosine phosphorylation
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123milieu upon exocytotic presynaptic stimulation [93–95]. It
is then taken up into the cytoplasm of neighboring cells
through gated Zn channels. The rapid inﬂux of Zn through
Ca-ion-permeable a-amino-3-hydroxy-5-methyl-4-isoxazole-
propionate/kainate channels triggers the generation of
reactive oxygen species (ROS) and is potentially neuro-
toxic [96].
In the above scenario, Zn’s activity is similar to that of
neurotransmitters, which are stored in membrane-enclosed
synaptic vesicles, are released by exocytosis, and activate
postsynaptic cells through transmitter-gated ion channels
[97–99]. Since Zn modulates both the current response
(mediated by excitatory and inhibitory neurotransmitter
receptors) and the efﬁcacy of transporter-driven neuro-
transmitter reuptake [100], synaptically released Zn has
been proposed to function as an important regulator of
synaptic transmission and plasticity [101, 102], or as an
‘‘atypical neurotransmitter’’ [103]. ZnT3 is highly expres-
sed on synaptic vesicle membranes and is essential for
loading Zn into synaptic vesicles.
Although ZnT3-KO mice show a loss of stainable Zn in
synapses [104], they are behaviorally normal except for an
enhanced susceptibility to kainite-induced seizures [105].
Recently, however, it was revealed that the ZnT3-KO mice
exhibit age-dependent deﬁcits in learning and memory that
are not apparent in young animals. This age-dependent
cognitive phenotype might be owing to its decreased level
in the hippocampus [106]. In addition, extracellular-signal-
regulated kinase 1 and 2 (Erk1/2) activation is reduced in
the hippocampal mossy ﬁbers in ZnT3-KO mice, suggesting
that ZnT3 is involved in the presynaptic Erk1/2 signaling
required for hippocampus-dependent memory [107].
Takeda et al. [17] reported that Zn chelation with clioquinol
inhibits hippocampal long-term potentiation and cognitive
behavior. This evidence suggests that synaptic Zn acts as a
neurotransmitter for maintaining the synaptic environment.
Zn has been identiﬁed as an endogenous GPCR 39
(GPR39) agonist, and the concept that GPR39 is the Zn-
sensing receptor in the brain is consistent with Zn’s role as
a neurotransmitter or ﬁrst messenger [108, 109]. Intercel-
lular Zn communication mediated through the Zn-sensing
GPR39 is also involved in regulating epithelial cell repair
[110] and endocrine pancreatic function [111]. Also sup-
porting Zn’s role in neurotransmission, Hosie et al. [112]
identiﬁed two Zn-binding sites and characterized a third in
the c-aminobutyric acid receptor, using site-directed
mutagenesis. In addition, Hirzel et al. [113] produced
knock-in mice carrying the mutation D80A (a constructed
Zn-binding site) in the glycine receptor alpha1 subunit
gene to show that Zn modulates neurotransmission. It is
also known that Zn inhibits N-methyl-D-aspartate receptor
activity through a dual mechanism, a voltage-dependent
channel block and a voltage-independent reduction in the
probability of the channel opening [114–116]. Thus, it is
likely that Zn acts as a neurotransmitter in addition to its
other roles in the neural system.
Zn as an intracellular signaling molecule, or the second
messenger
Several intracellular second messengers have been identi-
ﬁed, including 30,50-cyclic adenosine monophosphate
(cAMP), Ca
2?,3 0,50-cyclic guanosine monophosphate
(cGMP), nitric oxide (NO), ROS, and lipid mediators [117].
Zn has also appeared as a potential intracellular signaling
molecule in mitosis in starﬁsh oocytes [118]. Recently, an
essential role for Zn in arresting second metaphase exit has
been reported. This suggests that Zn has the potential to act
as an intracellular signaling molecule to regulate the
developmental program in vertebrate fertilization [4, 5]. It
has also been reported that Zn itself affects a variety of
signaling molecules, including PKC, Ca/calmodulin-
dependent protein kinase II, Erk1/2, cAMP-dependent
protein kinase, protein tyrosine phosphatase, and caspase-3
[119–125]. In addition, Zn activates ion channels such as
the transient receptor potential ankyrin 1 [126, 127], ATP-
sensitive K
? [128], and large-conductance Ca-activated K
?
[129] channels. Together, these ﬁndings suggest that Zn
may function as an intracellular signaling molecule or
second messenger, if extracellular stimuli such as cytokines
and growth factors cause the intracellular Zn status to
change, either independently, or in a manner dependent on
the transcriptional changes of Zn transporters or MTs.
We have proposed that Zn signaling can be divided into
EZS, which is directly and rapidly induced by an extra-
cellular stimulus, and LZS, which depends on transcrip-
tional changes to MTs, Zn transporters, and other
Zn-related molecules [19] (Fig. 3). ZIP6/Liv1 is required
for the epithelial–mesenchymal transition in the zebraﬁsh
gastrula organizer, because it is essential for the nuclear
retention of the E-cadherin repressor Snail (Fig. 2a) [20].
Since ZIP6/Liv1 expression in the zebraﬁsh organizer is
dependent on STAT3 activation, any extracellular stimulus
regulating STAT3 activation could change the intracellular
Zn level by inducing changes in Zn transporters such as
ZIP6/Liv1. TLR4 also alters the intracellular free Zn level,
which it decreases by inducing changes in Zn transporter
expression in dendritic cells (Fig. 2e) [78] and in pul-
monary endothelial cells [130]. These observations support
the idea that Zn acts as an intracellular second messenger,
that is, as a molecule whose intracellular status is altered in
response to an extracellular stimulus and that is capable of
transducing the extracellular stimulus into an intracellular
signaling event.
The role of Zn as a second messenger is further sup-
ported by our ﬁndings that ZIP13 is required for the BMP/
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(Fig. 2b) [23], that ZIP14 is involved in GPCR-mediated
signal transduction through cAMP basal level regulation
(Fig. 2c) [36], and that FceRI-stimulation-induced PKC
activation is dependent on ZnT5 in mast cells (Fig. 2d)
[43]. Another example showing that Zn transporters are
involved in signaling pathways is that cation diffusion
facilitator 1, a structural homologue of ZnT1 in Caeno-
rhabditis elegans, might mediate Raf-1 activation by
directly interacting with Raf-1 and removing Zn from the
Raf-1 cysteine-rich domain [131]. Thus, extracellular
stimuli can affect intracellular signaling pathways by
changing the intracellular Zn status through changes in the
expression of Zn transporters and other Zn-related mole-
cules; this exempliﬁes the LZS type (Fig. 3)[ 19].
EZS, on the other hand, is exempliﬁed by the tran-
scription-independent increase in intracellular Zn level that
occurs in mast cells some minutes after extracellular
stimulation; we call this phenomenon a ‘‘Zn wave’’ (Fig. 6)
[21]. The Zn wave originates from the region of the
endoplasmic reticulum and depends on Ca
2? inﬂux and
Erk1/2 activation in mast cells (Fig. 6b). Since extracel-
lular Zn is not involved in the Zn wave, and it is induced
within several minutes of FceRI stimulation, Zn here acts
as an intracellular signaling molecule (Fig. 6). Using the
Zn probe FluoZin-3, Haase et al. [132] revealed that the
intracellular Zn level is elevated in peripheral blood
mononuclear cells after phorbol 12-myristate 13-acetate
stimulation, and in human leukocytes, especially mono-
cytes, with physiological stimulation [133]. In addition,
ZIP7 is reported to regulate intracellular Zn on the endo-
plasmic reticulum membrane [134]. It is also possible that
transporters and channels other than ZIP or ZnT family
members generate Zn waves in individual cell types with
various types of stimulation. In any case, the precise
molecular mechanisms generating the Zn wave are still
elusive (Fig. 7a).
Outside intracellular compartments, Zn-buffering pro-
teins such as MTs are believed to be a major source of free
Zn released into the cytosol space in response to an
extracellular stimulus [135–137]. Zn is rapidly released
from MTs by nitrosylation or by thiol ligand oxidation.
Ultraviolet A irradiation can induce the generation of ROS,
which might oxidize thiols in MTs and induce transient
increases in intracellular free Zn level [138]. In patholog-
ical situations, N-methyl-D-aspartate receptor activation
might induce endogenous NO synthesis and increase
intracellular free Zn level by liberating Zn from MTs [139].
The liberation of intracellular Zn and the overactivation of
potassium channels were proposed to be important com-
ponents of nitrosative stress-induced neuronal death [140].
The liberated Zn induces its toxicity to neurons via acti-
vation of 12-lipoxygenase and mitogen-activated protein
kinase [141]. The NO donor S-nitrosocysteine (SNOC)
both increases free Zn level and inhibits LPS-induced
tumor necrosis factor alpha and interleukin-1 beta release.
This SNOC-induced increase in intracellular free Zn level
may therefore mediate SNOC’s inhibitory effect via
increased cGMP level [142]. In addition, cytokine stimu-
lation sometimes induces NO production, thereby
enhancing the intracellular free Zn level [143]. These
reports indicate that Zn released from oxidative-reaction-
stimulated MTs contributes to the EZS-type regulation of
intracellular phenomena (Fig. 7b).
Conclusion and future prospects
As discussed in this review, Zn is clearly involved in
regulating a wide variety of physiological responses.
Although most Zn studies have focused on the general
maintenance of its homeostasis, recent studies have shown
that Zn’s functions are far more extensive than might be
Fig. 6 FceRI increases intracellular free Zn levels, Zn wave: a type
of early Zn signaling. a The intracellular Zn level increases within
several minutes after antigen stimulation. To monitor the intracellular
Zn level, mast cells were treated with the cell-permeable ﬂuorescent
Zn indicator Newport Green. Newport Green ﬂuorescence remained
steady in the cytoplasm, but gradually increased in the perinuclear
and nuclear areas upon FceRI stimulation. We named this phenom-
enon a ‘‘Zn wave.’’ b Early Zn signaling in mast cells. Extracellular
antigen stimulation induces a Zn wave—a rapid alteration in
intracellular Zn level—through the activation of Ca
2? and extra-
cellular-signal-regulated kinase 1 and 2 (Erk1/2) signaling, which
might positively affect the signal for inﬂammatory cytokine-mediated
allergic reactions. This suggests that Zn has a role as an intracellular
signaling molecule, transducing extracellular stimuli to physiological
responses. Violet ovals Zn gatekeepers. (a Modiﬁed from Yamasaki
et al. [21])
1130 J Biol Inorg Chem (2011) 16:1123–1134
123implied by its simple deﬁnition as an essential nutrient. The
intracellular Zn status is dynamically altered in response to
a variety of extracellular stimuli, and this change in Zn
status is capable of transducing extracellular stimuli into
intracellular signaling events. On the basis of the evidence
accumulated, we have proposed that Zn acts as a signaling
molecule in at least two modes: transcription-independent
EZS and transcription-dependent LZS (Fig. 3)[ 19]. Sev-
eral important questions remain to be resolved: What
extracellular stimulus, in which cells or tissues, regulates
the expression of the Zn transporters and channels involved
in Zn signaling? How are these Zn transporters or channels
activated in response to the extracellular stimulus? How
does each Zn transporter speciﬁcally regulate the intra-
cellular signaling pathway? How do Zn transporters
transfer Zn into their target molecules? Is there any chap-
eron which transfers Zn from a given transporter to its
speciﬁc target molecule? What are the target molecules and
biological roles of Zn signaling? Another question is how
to speciﬁcally monitor and visualize intracellular free Zn in
vivo with high resolution; this will require the use of
chemical compounds [92], multitracer detection devices
[144], and two-photon and X-ray ﬂuorescence microscopy
[145, 146]. The development of drugs for Zn-related
diseases is another emerging avenue of study. Modiﬁed
Zn-containing pharmaceuticals may speed the discovery of
Zn-signaling action points [147]. A deeper understanding
of the early and late Zn signals and signaling dysfunctions
will provide novel insights into Zn’s roles as a signaling
molecule in mammalian health and diseases.
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